Currently out of the existing stock ratings of Andrew Galler, 13 are a BUY (59.09%), 2 are a SELL (9.09%), 7 are a HOLD (31.82%).

Andrew Galler

Work Performance Price Targets & Ratings Chart

Analyst Andrew Galler, carries an average stock price target met ratio of 74.72% that have a potential upside of 26.56% achieved within 226 days.

Andrew Galler’s has documented 52 price targets and ratings displayed on 6 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on IMCR, Immunocore Holdings Ltd at 13-Dec-2024.

Wall Street Analyst Andrew Galler

Analyst best performing recommendations are on ARWR (ARROWHEAD PHARMACEUTICALS).
The best stock recommendation documented was for ARWR (ARROWHEAD PHARMACEUTICALS) at 11/29/2022. The price target of $37 was fulfilled within 22 days with a profit of $7.01 (23.37%) receiving and performance score of 10.62.

Average potential price target upside

of $53.27 (25.02%) on VRTX (VERTEX PHARMACEUTICALS).
of $15.21 (8.74%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $7.52 (31.42%) on VIR (VIR BIOTECHNOLOGY).

FOLD Amicus Therapeutics VIR Vir Biotechnology VRTX Vertex Pharmaceuticals ARWR Arrowhead Pharmaceuticals IMCR Immunocore Holdings Ltd ALNY Alnylam Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Kristen Kluska (CANTOR FITZGERALD)